Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 24
- Registration Number
- NCT06745882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06743126
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 105
- Registration Number
- NCT06735326
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLS) (MK-3475-01G/KEYMAKER U01)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06731907
Study of Novel Treatment Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma.
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT06727565
Safety, Effectiveness, and Pharmacokinetics (the Movement of Drug Into, Through and Out of the Body) of BNT327 (an Investigational Therapy) in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 982
- Registration Number
- NCT06712316
A Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck with No Distant Metastases
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 408
- Registration Number
- NCT06699212
- Locations
- 🇺🇸
Cancer Clinic, Lexington, Kentucky, United States
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06694454
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 880
- Registration Number
- NCT06692738
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 380
- Registration Number
- NCT06682611
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath